Limited small cell lung cancer: Possible prognostic impact of initial chemotherapy doses

Arriagada, R.; T, Le Chevalier; Thomas, François; Ruffié, Pierre; H, de Cremoux; Martin, M.; Duroux, P; Dewar, JA; Sancho‐Garnier, H.

doi:10.1016/0169-5002(90)90354-o

Lung Cancer

1990

DOI: 10.1016/0169-5002(90)90354-o

|View full text |Cite

Limited small cell lung cancer: Possible prognostic impact of initial chemotherapy doses

R. Arriagada

Le Chevalier T²,

François Thomas³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1990

1994

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 11 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

Rosell¹,

Carles²,

Abad³

et al. 1992

Invest New Drugs

View full text Add to dashboard Cite

Seventeen patients with small cell lung cancer entered a phase II trial testing the feasibility of adding high dose epirubicin (100-120 mg/m2, day 1) in combination with etoposide (60-80 mg/m2, days 1-5) and cisplatin (70 mg/m2, day 1) courses repeated every three weeks. Complete responders received thoracic (40 Gy) and prophylactic cranial (30 Gy) irradiation. Sixteen patients were evaluable for response and toxicity. Myelosuppression was the dose-limiting side effect. Neutropenic fever was observed in eight patients (53%) and stomatitis in six (40%). No patient had a greater than 14% decline in the cardiac ejection fraction. Strict adherence to the dose-schedule designed was impossible as doses were trimmed and delayed in 30% of instances. The overall objective response rate was 81% (95% confidence limits, 62% to 100%), in limited disease there were complete remissions in 57%. With a 16 months median follow-up, overall median survival was 13 months. This study was unable to prove the feasibility of epirubicin escalation when added to etoposide-cisplatin combination, hampering the dose-intensification Norton-Simon model test.

show abstract

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

Rosell¹,

Carles²,

Abad³

et al. 1992

Invest New Drugs

View full text Add to dashboard Cite

show abstract

Phase II study of alternating combination chemotherapy in small cell lung cancer

Pujol¹,

Démoly²,

Gautier³

et al. 1991

Lung Cancer

View full text Add to dashboard Cite

Alternating radiotherapy and chemotherapy in limited small cell lung cancer: the IGR protocols

et al. 1994

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Limited small cell lung cancer: Possible prognostic impact of initial chemotherapy doses

Cited by 11 publications

References 0 publications

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer

Phase II study of alternating combination chemotherapy in small cell lung cancer

Alternating radiotherapy and chemotherapy in limited small cell lung cancer: the IGR protocols

Contact Info

Product

Resources

About